接受HyperCVAD治疗的成人急性淋巴细胞白血病患者微小残留病状态动态变化的描述及其预后意义
研究142例接受HyperCVAD治疗的成人急性淋巴细胞白血病患者,采用多参数流式细胞术或BCR-ABL1逆转录聚合酶链反应评估微小残留病。多因素分析显示任何时间点达到微小残留病阴性者总生存(HR 0.43;P=0.01)和无事件生存(HR 0.27;P<0.01)均显著更优。121例在启动HyperCVAD后90天内评估微小残留病者中50%(n=61)达到阴性,中位达阴性时间68天,达阴性时间与无事件生存显著相关(P=0.009)但与总生存无关(P=0.19)。
要点
- 任何时间点达到微小残留病阴性者总生存(HR 0.43;P=0.01)和无事件生存(HR 0.27;P<0.01)显著更优。
- 90天内评估的121例中50%(n=61)达到微小残留病阴性,中位达阴性时间68天。
- 达微小残留病阴性时间与无事件生存显著相关(P=0.009),与总生存无关(P=0.19)。
核心结论
- 接受HyperCVAD治疗的成人急性淋巴细胞白血病患者中,达到微小残留病阴性者总生存和无事件生存显著更优,达阴性时间越早无事件生存越好。
研究设计与样本
- 研究纳入142例接受HyperCVAD治疗的成人急性淋巴细胞白血病患者,回顾10年期间数据,微小残留病采用多参数流式细胞术评估,费城染色体阳性急性淋巴细胞白血病患者采用逆转录聚合酶链反应检测BCR-ABL1易位。
主要发现
- 多因素分析中,任何时间点达到微小残留病阴性者总生存显著更优(HR 0.43;P=0.01),无事件生存显著更优(HR 0.27;P<0.01)。
- 121例在启动HyperCVAD后90天内不同时间点评估微小残留病者中,50%(n=61)达到微小残留病阴性。
- 达到微小残留病阴性者中位达阴性时间为68天。
- 达微小残留病阴性时间与无事件生存显著相关(P=0.009),与总生存无显著相关(P=0.19)。
关键数值与推荐
- 微小残留病阴性者总生存HR 0.43(P=0.01)。
- 微小残留病阴性者无事件生存HR 0.27(P<0.01)。
- 90天内评估的121例中微小残留病阴性率为50%(n=61)。
- 达微小残留病阴性中位时间68天。
- 达微小残留病阴性时间与无事件生存相关P=0.009,与总生存相关P=0.19。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HyperCVAD is a commonly-used regimen for adults with newly-diagnosed acute lymphoblastic leukemia (ALL). However, relatively little is known about the application of minimal residual disease (MRD) detection with this treatment. To address this, we studied 142 adults with ALL treated with hyperCVAD over a 10-year period who had MRD assessed by either multi-parameter flow cytometry or (for patients with Philadelphia chromosome positive ALL) reverse transcriptase polymerase chain reaction for the BCR-ABL1 translocation. In a multivariate analysis, patients who achieved MRD negativity (MRDNeg ) at any point had significantly better overall survival (OS; hazard ratio [HR] 0.43; P = .01) and event-free survival (EFS; HR 0.27; P < .01). Of 121 patients with MRD assessed at various points within 90 days of starting hyperCVAD, 50% (n = 61) had achieved MRDNeg . Among those that became MRDNeg , the median time to MRDNeg was 68 days. Time to MRDNeg was significantly associated with EFS (P = .009), but not OS (P = .19), implying increasingly better EFS the earlier MRDNeg is achieved. These data add to our understanding of MRD assessment during treatment with hyperCVAD, aide clinicians with predicting relapse risk, and provide additional historical data on which future clinical trials can be designed.
引用
- Cassaday RD, Stevenson PA, Wood BL, et al. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. Am J Hematol. 2018. PMID: 29318644. doi:10.1002/ajh.25030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。